An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires
-
-
-
-
-
Vienna, Austria
- Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
-
-
-
-
-
Brussels, Belgium
- Cliniques universitaires Saint-Luc
-
-
-
-
-
São Paulo, Brazil
- Sociedade Beneficente de Senhoras Hospital Sírio-Libanês
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- University of Alberta - Women and Children's Health Research Institute
-
-
-
-
-
Bogotá, Colombia
- Fundacion Cardioinfantil
-
-
-
-
-
Lyon, France
- Groupement Hospitalier Est Hopital, Femme Mère Enfant de Lyon
-
Toulouse, France, 31059
- CHU de Toulouse - Hôpital des Enfants
-
-
-
-
-
Hanover, Germany
- Medizinische Hochschule
-
-
-
-
-
Bergamo, Italy, 24127
- Azienda Ospedaliera Papa Giovanni XXIII - Unita di Pediatria
-
Roma, Italy
- Ospedale Pediatrico Bambino Gesu'
-
-
-
-
-
Beirut, Lebanon
- Hotel Dieu de France, Alfred Naccache
-
-
-
-
-
Zapopan, Mexico
- Consultario de Joshue David Covarrubias Esquer
-
-
-
-
-
Warsaw, Poland
- Instytut Pomnik Centrum, Zdrowia Dziecka
-
-
-
-
-
Singapore, Singapore
- KK Women's and Children's Hospital
-
-
-
-
-
Istanbul, Turkey (Türkiye), 34010
- Koc University Hospital
-
-
-
-
-
Birmingham, United Kingdom
- Birmingham Children's Hospital
-
London, United Kingdom
- King's College Hospital NHS Foundation Trust
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Orlando, Florida, United States, 32803
- Advent Health
-
-
New York
-
The Bronx, New York, United States, 10461
- Children's Hospital at Montefiore
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Children Hospital of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
San Antonio, Texas, United States, 78229
- University of Texas, Health Science Center San Antonio
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Provide informed consent and assent (as applicable) per Institutional Review Board/Ethics Committee (IRB/EC)
- Completion of study MRX-502
Exclusion Criteria:
- Any female who is pregnant or lactating or who is planning to become pregnant
- Administration of prohibited medication between the MRX-502 EOT visit and the MRX 503 Baseline Visit (Day 0)
- History of non-compliance in study MRX-502, non-adherence to medical regimens, unreliability, mental instability or incompetence that could compromise the validity of informed consent or lead to non-adherence with the study protocol based on Investigator judgment
- Experienced an adverse event (AE) or serious adverse event (SAE) related to maralixibat during the MRX-502 study that led to permanent discontinuation of the subject from maralixibat
- Any other conditions or laboratory abnormalities that, in the opinion of the Investigator or Sponsor Medical Monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study
- Cognitive impairment of the subject or caregiver that would, in the opinion of the investigator, preclude appropriate understanding of study information and compliance with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Maralixibat
All subjects will receive Maralixibat oral solution
|
All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) twice daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score
Time Frame: From Baseline to Weeks 75-78
|
The Score on the ItchRo scale is a score on a 5-point scale from 0 (no itch) to 4 (very severe itch)
|
From Baseline to Weeks 75-78
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maintenance of ItchRO(Obs) Response (Weeks 15 - 26)
Time Frame: Week 15 - 26
|
Maintenance of treatment effect is defined as the proportion of participants in the MRX-MRX treatment group (MRX-502 and MRX-503 data for subjects on MRX in the MRX-502 study) who obtain an ItchRO (Obs) response from Week 15 to Week 26 in Study MRX-503 in the primary cohort and PFIC cohort.
|
Week 15 - 26
|
|
Proportion of ItchRO(Obs) Responders Over Time
Time Frame: Baseline to EOT
|
Proportion of ItchRO responders over time at each study visit using the 4-week study period prior to the visit as per ItchRO(Obs) responder definition.
|
Baseline to EOT
|
|
Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Frequency Score
Time Frame: From Baseline to Weeks 75-78
|
The Score on the ItchRo scale is a score on a 5-point scale from 0 (no itch) to 4 (very severe itch)
|
From Baseline to Weeks 75-78
|
|
Mean Change From Baseline Over Time in Total Serum Bile Acid (sBA) Levels
Time Frame: Baseline to week 70
|
Mean change from baseline over time in total serum bile acid (sBA) levels
|
Baseline to week 70
|
|
Proportion of Subjects Who Experience an sBA Control Over Time From Week 18 to Week 26
Time Frame: From Week 18 to Week 26
|
Proportion of subjects who experience an sBA control over time from Week 18 to Week 26
|
From Week 18 to Week 26
|
|
Change From Baseline in Height Z-score
Time Frame: From baseline to Week 70
|
Height-for-age Z-score measures a participant's height relative to a reference population of children of the same age and sex.
Z-scores were derived using World Health Organization growth charts for participants less than 24 months of age and Centers for Disease Control and Prevention growth charts for participants 24 months of age or older.
A Z-score of 0 represents the population mean for age and sex.
Positive Z-scores indicate height above the reference population mean, and negative Z-scores indicate height below the reference population mean.
Higher Z-scores generally indicate greater linear growth relative to the reference population.
Change from baseline was calculated as post-baseline height-for-age Z-score minus baseline height-for-age Z-score.
|
From baseline to Week 70
|
|
Change From Baseline in Weight Z-score
Time Frame: From Baseline to Week 70
|
Weight-for-age Z-score measures a participant's weight relative to a reference population of children of the same age and sex.
Z-scores were derived using World Health Organization growth charts for participants less than 24 months of age and Centers for Disease Control and Prevention growth charts for participants 24 months of age or older.
A Z-score of 0 represents the population mean for age and sex.
Positive Z-scores indicate weight above the reference population mean, and negative Z-scores indicate weight below the reference population mean.
Higher Z-scores generally indicate greater body weight relative to the reference population.
Change from baseline was calculated as post-baseline weight-for-age Z-score minus baseline weight-for-age Z-score.
|
From Baseline to Week 70
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MRX-503
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.